ライフサイエンスコーパス: tachycardia

1 oked by adenosine (bradycardia) vs. hypoxia (tachycardia).

2 y tachycardia and atrioventricular reentrant tachycardia).

3 3, couplets; and 4, nonsustained ventricular tachycardia).

4 n markedly reduced the burden of ventricular tachycardia.

5 itter acetylcholine on heart rate leading to tachycardia.

6 re hypertrophy, and nonsustained ventricular tachycardia.

7 substrate and critical sites for ventricular tachycardia.

8 on of post-myocardial infarction ventricular tachycardia.

9 anism of spontaneous polymorphic ventricular tachycardia.

10 clinical permanent junctional reciprocating tachycardia.

11 n for post-myocardial infarction ventricular tachycardia.

12 clinical permanent junctional reciprocating tachycardia.

13 icular fibrillation or pulseless ventricular tachycardia.

14 ia causes hyperventilation, hypertension and tachycardia.

15 s study was freedom from recurrent AF/atrial tachycardia.

16 ventricular complexes and focal ventricular tachycardia.

17 in catecholaminergic polymorphic ventricular tachycardia.

18 matic episodes of atrioventricular reentrant tachycardia.

19 th catecholaminergic polymorphic ventricular tachycardia.

20 ion), there were 680 episodes of ventricular tachycardia.

21 for atrial fibrillation or supraventricular tachycardia.

22 tricular fibrillation /pulseless ventricular tachycardia.

23 ue to serious adverse events of vomiting and tachycardia.

24 ise in the management of inappropriate sinus tachycardia.

25 ined history of 6577 episodes of ventricular tachycardia.

26 brillation, atrial flutter, and focal atrial tachycardia.

27 vasive cardiac radioablation for ventricular tachycardia.

28 -voltage regions and aids ablation of atrial tachycardias.

29 drove 30% (7/23) of our postablation atrial tachycardias.

30 g the left atrium compared with right atrial tachycardias.

31 cordings; and (4) higher incidence of atrial tachycardia (15% versus 41%, P=0.02) and atrial fibrilla

32 ]; P<0.01), slower orthodromic reciprocating tachycardia (176+/-44 beats per minute versus 229+/-31 b

33 3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%), upper gastrointest

34 Among 16 critical sites for ventricular tachycardia, 3 (18%) were in a discordant region of scar

35 8; catecholaminergic polymorphic ventricular tachycardia, 3; short QT syndrome, 1; and arrhythmogenic

36 ), catecholaminergic polymorphic ventricular tachycardia (4%), arrhythmogenic right ventricular cardi

37 hese, 177 (28.8%) had idiopathic ventricular tachycardia, 408 (66.5%) had symptomatic PVCs, and 29 (4

38 trial fibrillation (28.8%), and focal atrial tachycardia (9.5%).

39 Acute procedural success of atrial tachycardia ablation in congenital heart patients was no

40 ter shows promise for decreasing ventricular tachycardia ablation procedure time and improving outcom

41 Patients referred for atrial tachycardia ablation underwent dense electroanatomic poi

42 d for post-myocardial infarction ventricular tachycardia ablation were included.

43 lves, who underwent scar-related ventricular tachycardia ablation, were analyzed to correlate the tim

44 ntricular tachycardia, sustained ventricular tachycardia, aborted sudden cardiac death, or sudden car

45 We prospectively used RM to study tachycardia activation in the previously ablated left at

46 icular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular acces

47 Recurrent ventricular tachycardia among survivors of myocardial infarction wit

48 er normoxic conditions displayed a transient tachycardia and a biphasic caudal arterial blood pressur

49 The RATE Registry (Registry of Atrial Tachycardia and Atrial Fibrillation Episodes) is a prosp

50 a mechanisms (atrioventricular nodal reentry tachycardia and atrioventricular reentrant tachycardia).

51 r sudden cardiac death caused by ventricular tachycardia and fibrillation (VT/VF).

52 re catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] and 11 [4%], r

53 of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially the RYR2 ge

54 Catheter ablation for ventricular tachycardia and premature ventricular complexes (PVCs) i

55 Ventricular tachycardia and premature ventricular complexes (PVCs) m

56 unts, at least in part, for the induction of tachycardia and the arrhythmogenic potency of this drug.

57 CHD who had atrioventricular nodal reentrant tachycardia and were treated with catheter ablation.

58 esigned to document the prevalence of atrial tachycardia and/or fibrillation (AT/AF) of any duration

59 rhythm (ventricular fibrillation/ventricular tachycardia), and ST-elevations-had excellent discrimina

60 c VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing episodes.

61 vents involving palpitations, chest pain, or tachycardia, and 58.0% (95% CI, 52.2 to 63.7) involved p

62 ic instability characterized by bradycardia, tachycardia, and asystole); 22 (9%) patients experienced

63 Toxicities included fever, tachycardia, and hypotension.

64 tolerated sustained monomorphic ventricular tachycardia, and male sex predicted lethal arrhythmias a

65 0.05), and abolished the pressor responses, tachycardia, and QT interval prolongation.

66 clinical permanent junctional reciprocating tachycardia, and these patients had more syncope (5/11 [

67 Post ablation atrial tachycardias are characterized by low-voltage signals th

68 assessed by counting episodes of ventricular tachycardia, as recorded by ICDs.

69 s is a critical part of perimitral reentrant tachycardia, as well as an important substrate of persis

70 ients with sustained monomorphic ventricular tachycardia associated with coronary disease were analyz

71 ria unequivocally differentiate focal atrial tachycardia (AT) caused by microreentry, triggered activ

72 we assess the efficacy of optogenetic atrial tachycardia (AT) termination in human hearts using a str

73 ibility of optogenetic termination of atrial tachycardia (AT), comparing two different illumination s

74 ion mapping of reentrant scar-related atrial tachycardias (AT) allows efficient radiofrequency ablati

75 come was symptomatic recurrence of AF/atrial tachycardia/atrial flutter lasting >30 seconds, determin

76 Atrial tachycardias (ATs) are a significant source of morbidity

77 on atypical atrioventricular nodal reentrant tachycardia (AVNRT) are scarce, and the optimal ablation

78 Atrioventricular nodal reentrant tachycardia (AVNRT) is considered a sporadic disease occ

79 choice for atrioventricular nodal reentrant tachycardia (AVNRT).

80 sons for rapid response team activation were tachycardia/bradycardia at 29% (217/748), respiratory di

81 piratory distress/low SpO2 at 43% (423/977), tachycardia/bradycardia at 33% (327/977), and hypotensio

82 ed sympathoexcitation, pressor responses, or tachycardia but abolished the prolongation of QT interva

83 icular fibrillation or pulseless ventricular tachycardia, but without proven survival benefit.

84 Atrioventricular nodal reentrant tachycardia can complicate the course of patients with C

85 cular fibrillation and pulseless ventricular tachycardia) cardiac arrests.

86 In 2 ventricular tachycardia cases, absence of PN capture was achieved on

87 ng catecholaminergic polymorphic ventricular tachycardia, congenital long QT syndrome, and hypertroph

88 No supraventricular tachycardias converted to VT or ventricular fibrillation

89 th catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fibrillation (AF).

90 as catecholaminergic polymorphic ventricular tachycardia (CPVT) and long QT syndrome.

91 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition of abnormal heart rhyt

92 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-th

93 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal genetic arrhy

94 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome c

95 or catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear.

96 nt catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading cause of sudden death in a

97 In catecholaminergic polymorphic ventricular tachycardia (CPVT), cardiac Purkinje cells (PCs) appear

98 nd catecholaminergic polymorphic ventricular tachycardia (CPVT).

99 nd catecholaminergic polymorphic ventricular tachycardia (CPVT).

100 ng catecholaminergic polymorphic ventricular tachycardia (CPVT).

101 All tachycardias crossed an isthmus (median, 0.52 mV, 13 mm)

102 ectrograms were nonfractionated, and <50% of tachycardia cycle length could be mapped.

103 ATs had nonfocal activation, with >/=90% of tachycardia cycle length identified with electroanatomic

104 calized fractionated electrograms (>/=35% of tachycardia cycle length) at the site of successful abla

105 nated electrograms (117+/-18 ms; 44+/-13% of tachycardia cycle length) within the carousel interrupte

106 rams along the carousel encompassed the full tachycardia cycle length, and surrounding activation mov

107 Tachycardia cycle lengths were 368.0+/-43.1 and 365.8+/-

108 ardiomyopathy and an ICD who had ventricular tachycardia despite antiarrhythmic drug therapy, there w

109 ardiomyopathy and an ICD who had ventricular tachycardia despite the use of antiarrhythmic drugs.

110 bradycardia, supraventricular or ventricular tachycardia) developed.

111 e of adenosine effect on focal AT identifies tachycardia due to microreentry.

112 nuous right ventricular apical pacing during tachycardia effectively distinguishes between atypical a

113 ocardial infarction, spontaneous ventricular tachycardia episodes (n = 3) were preceded by significan

114 Focal atrial tachycardia (FAT) is extremely difficult to map and abla

115 iac death (SCD) may be caused by ventricular tachycardia/fibrillation or pulseless electric activity/

116 m had a higher incidence of organized atrial tachycardia/flutter (24/33 [73%] versus 11/31 [35%]; P=0

117 for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardiac deaths.

118 vere health consequences, including anxiety, tachycardia, hallucinations, violent behavior, and psych

119 Tachycardia (heart rate > 90 beats/min) (odds ratio, 2.7

120 the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conduct

121 ntricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in either outc

122 in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35 to 1.42; p < 0.0001)

123 tolerated sustained monomorphic ventricular tachycardia (HR: 2.19; p = 0.023), and male sex (HR: 2.4

124 e, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and other here

125 nting arrhythmia was intra-atrial re-entrant tachycardia (IART) (61.6%), followed by atrial fibrillat

126 Intra-atrial reentrant tachycardia (IART) after the Fontan operation had an ear

127 Mild, transient events were tachycardia in 1, alanine transaminase elevation in 1, a

128 RM-guided ablation interrupted the tachycardia in 19 of 20 cases with the first ablation se

129 ated AF to sinus rhythm or atrial flutter or tachycardia in 59% (PAF), 37% (PeAF), and 19% (LPeAF) of

130 andard therapy for treating supraventricular tachycardia in children and adults without transplantati

131 length) within the carousel interrupted the tachycardia in every LR case.

132 emic substrate causing left ventricular (LV) tachycardia in Latin America.

133 Exercise induced postural tachycardia in one third of GWI subjects (Stress Test Ac

134 ation did not improve freedom from AF/atrial tachycardia in patients with paroxysmal or persistent AF

135 cin can cause rapid, polymorphic ventricular tachycardia in the absence of QT prolongation, indicatin

136 reduced adrenergically mediated ventricular tachycardia in treated mice, (3) reverted ultrastructura

137 Tachycardiomyopathy or tachycardia-induced cardiomyopathy (TCM) has been known

138 Elevated resting Ca(2+) levels and a tachycardia-induced increase in diastolic Ca(2+) were as

139 Acute success was lower for tachycardias involving the left atrium compared with rig

140 Post-infarct ventricular tachycardia is associated with channels of surviving myo

141 Supraventricular tachycardia is common after heart transplantation.

142 Tachycardia is common in septic shock, but many patients

143 ategy for ablation of scar-based ventricular tachycardia is delivering multiple lesions in a linear p

144 Although the rate of idiopathic ventricular tachycardia is similar across sexes, women have a higher

145 an episode of AF, atrial flutter, or atrial tachycardia lasting >30 seconds after a 3-month blanking

146 ted ventricular fibrillation and ventricular tachycardia (lasting >/=30 seconds or recurrent symptoma

147 of ventricular fibrillation and ventricular tachycardia, leading to life-threatening arrhythmias.

148 a catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation (A4860G) show a unique

149 ic renal disease or nonsustained ventricular tachycardia, low-income prescription benefits subsidy, a

150 Left posterior fascicular ventricular tachycardia (LPF-VT) is frequently misdiagnosed as supra

151 going detailed epicardial and endocardial LV tachycardia mapping and ablation were included.

152 C), fatigue (in 65%), diarrhea (in 62%), and tachycardia (mean heart rate, >93 beats per minute).

153 The supraventricular tachycardia mechanism was typical slow/fast reentry in m

154 nsertion site and often coexisted with other tachycardia mechanisms (atrioventricular nodal reentry t

155 nodal reentry and atrioventricular reentrant tachycardia mediated by septal APs.

156 te goes uncontrolled for a prolonged period, tachycardia-mediated cardiomyopathy can occur.

157 brillator shock (n=4), sustained ventricular tachycardia (n=1), or sudden death (n=1), compared with

158 T notification for 105 patients (ventricular tachycardia, n = 44; pause/asystole, n = 36; polymorphic

159 ormed exclusively in 6 patients (ventricular tachycardia, n=1; PVC, n=5).

160 two patients in the brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients i

161 on was performed in 12 patients (ventricular tachycardia, n=2; PVC, n=10) and right ventricular ablat

162 In five patients with refractory ventricular tachycardia, noninvasive treatment with electrophysiolog

163 tic significance of nonsustained ventricular tachycardia (NSVT) in patients with hypertrophic cardiom

164 Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndro

165 rial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickn

166 f multiple beats of nonsustained ventricular tachycardia (NSVT).

167 A reduction in episodes of ventricular tachycardia occurred in all five patients.

168 year-old woman presenting with a ventricular tachycardia of 190 beats/min was administered amiodarone

169 ndly decreased vulnerability for ventricular tachycardia on programmed right ventricular and burst st

170 om 8 to 96 months), regular supraventricular tachycardia or benign atrial fibrillation (shortest RR i

171 t (OHCA) with initial rhythms of ventricular tachycardia or pulseless ventricular fibrillation (VT/VF

172 ing study criteria scheduled for ventricular tachycardia or PVC ablation over a 9-month period.

173 efibrillation for IHCA caused by ventricular tachycardia or ventricular fibrillation was associated w

174 ts with IHCA caused by pulseless ventricular tachycardia or ventricular fibrillation were stratified

175 t, successful defibrillation for ventricular tachycardia or ventricular fibrillation) were analyzed w

176 patients with an IHCA caused by ventricular tachycardia or ventricular fibrillation, the rate of 1-y

177 successful conversion of induced ventricular tachycardia or ventricular fibrillation.

178 torm (ES), in which a cluster of ventricular tachycardias or ventricular fibrillation, negatively aff

179 re affected vital signs (fever, hypotension, tachycardia, or tachypnoea; 96 [44%] of 217 patients wit

180 tricular fibrillation, pulseless ventricular tachycardia, or unknown shockable rhythm between January

181 period, there were 4 episodes of ventricular tachycardia over the next 46 patient-months, for a reduc

182 Secondary end points were inappropriate anti-tachycardia pacing and inappropriate ICD shock.

183 significant reduction in inappropriate anti-tachycardia pacings in both group and a significant redu

184 In 3 atrial tachycardia patients, PN displacement was not possible w

185 target arrhythmia was achieved in all atrial tachycardia patients; however, a nontargeted ventricular

186 resent as permanent junctional reciprocating tachycardia (permanent junctional reciprocating tachycar

187 Beta-receptor blockade does not alter the tachycardia phase to low intensity VNS, but can increase

188 nation is associated with consecutive atrial tachycardia procedures.

189 Respiratory failure, persistent ventricular tachycardia, profound shock refractory to inotropic agen

190 ing for at least 6 months and with unchanged tachycardia programming, were included.

191 Peak and mean sinus tachycardia rates were significantly reduced after RDN.

192 nd catecholaminergic polymorphic ventricular tachycardia received routine beta-blocker therapy and de

193 patients; however, a nontargeted ventricular tachycardia recurred in 1 patient at a median of 13 mont

194 ablation, and 71% remain free of ventricular tachycardia recurrence at 6-month median follow-up.

195 Tachycardia recurrence was observed in 54% of the patien

196 Long-term outcome with regard to tachycardia recurrence was worse in patients with comple

197 n, 6-month sustained monomorphic ventricular tachycardia recurrence, quality of life measured by the

198 of the arrhythmic focus without ventricular tachycardia recurrence.

199 nts had no sustained monomorphic ventricular tachycardia recurrence; the proportion of patients with

200 pattern of localized reentry (LR) in atrial tachycardia remains incompletely understood.

201 Notably, recurrent monomorphic ventricular tachycardia requiring >/=2 implantable cardioverter-defi

202 ution with recurrent episodes of ventricular tachycardia requiring emergent total artificial heart an

203 site of sudden cardiac death and ventricular tachycardia requiring treatment constituted the secondar

204 ization (n = 83), revascularization (n = 7), tachycardia resolution (n = 2), alcohol cessation (n = 1

205 on of gap junctions and promotes ventricular tachycardia, showing the functional significance of FXR1

206 In breakout tachycardias, splitting of wavefronts resulted in 2 to 4

207 I subjects (Stress Test Activated Reversible Tachycardia, START).

208 lar tachycardia within 24 hours (ventricular tachycardia storm), or appropriate ICD shock.

209 posite primary outcome of death, ventricular tachycardia storm, or appropriate ICD shock among patien

210 0%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2

211 CC causes a unique ventricular tachycardia substrate concentrated to the basal lateral

212 nd catecholaminergic polymorphic ventricular tachycardia-susceptibility gene (RYR2) identified a puta

213 int of long runs of nonsustained ventricular tachycardia, sustained ventricular tachycardia, aborted

214 Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac

215 into orthostatic hypotension (OH), postural tachycardia syndrome (POTS), or normal HUT groups.

216 nd catecholaminergic polymorphic ventricular tachycardia syndromes) should also be considered cardiom

217 mic inflammatory response syndrome criteria (tachycardia, tachypnea, leukocytosis, and fever) in surg

218 to catecholaminergic polymorphic ventricular tachycardia that feature lethal cardiac arrhythmias with

219 ctrocardiographic imaging during ventricular tachycardia that was induced by means of an implantable

220 In 8 mapped reentrant ventricular tachycardias, the circuits included regions of preserved

221 -rate cut-off (Arm B) or delayed ventricular tachycardia therapy (Arm C), compared with conventional

222 High-rate cut-off or delayed ventricular tachycardia therapy programming significantly reduced th

223 In idiopathic ventricular tachycardia, there was an increase in incidence rate wit

224 ial RF Ablation in Patients With Ventricular Tachycardia [THERMOCOOL VT]; NCT00412607).

225 hycardia (permanent junctional reciprocating tachycardia), they may also be diagnosed unexpectedly du

226 tionship of atrioventricular nodal reentrant tachycardia to congenital heart disease (CHD) and the ou

227 optical system in the setting of ventricular tachycardia to optimize mechanistic, multi-barrier cardi

228 ogically distinctive polymorphic ventricular tachycardia ('torsades de pointes').

229 Catecholaminergic polymorphic ventricular tachycardia type 2 (CPVT2) results from autosomal recess

230 ture ventricular contractions or ventricular tachycardia underwent catheter cryoablation or radiofreq

231 ients with high-risk, refractory ventricular tachycardia underwent treatment.

232 red for ablation of scar-related ventricular tachycardia underwent voltage maps during a minimum of 2

233 tion, occurrence of atrial flutter or atrial tachycardia, use of antiarrhythmic drugs, or repeat abla

234 rophic cardiomyopathy (HCM), and ventricular tachycardia-ventricular fibrillation (VT-VF).

235 ICD discharge-free survival for ventricular tachycardia/ventricular fibrillation >/= 240 beats per m

236 therapy but permits therapy for ventricular tachycardia/ventricular fibrillation (VF).

237 ICD termination of rapid ventricular tachycardia/ventricular fibrillation can reasonably be c

238 Patients with repetitive ventricular tachycardia/ventricular fibrillation episodes alternatin

239 S episode included a median of 7 ventricular tachycardia/ventricular fibrillation episodes.

240 es or prevents the recurrence of ventricular tachycardia/ventricular fibrillation in such patients.

241 substrate, BrS ECG pattern, and ventricular tachycardia/ventricular fibrillation inducibility.

242 imary end point of time to first ventricular tachycardia/ventricular fibrillation recurrence.

243 rmine whether ICD discharges for ventricular tachycardia/ventricular fibrillation were equivalent to

244 1) and less often presented with ventricular tachycardia/ventricular fibrillation, a witnessed arrest

245 time to death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, and heart failure

246 se/asystole, n = 36; polymorphic ventricular tachycardia/ventricular fibrillation, n = 14; other, n =

247 cardiac death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, or heart failure h

248 the time to first recurrence of ventricular tachycardia/ventricular fibrillation.

249 gment elevation MI, and 8.9% had ventricular tachycardia/ventricular fibrillation.

250 ntricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.

251 Outcomes of ventricular tachycardia (VT) ablation have been described in clinica

252 UNIVU module during scar-related ventricular tachycardia (VT) ablation.

253 Recurrence of ventricular tachycardia (VT) after ablation in patients with previou

254 ng catheter ablation of unstable ventricular tachycardia (VT) at our center.

255 Radiofrequency ablation (RFA) of ventricular tachycardia (VT) can fail because of inaccessibility to

256 H) ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest is unknown.

257 In vivo description of ventricular tachycardia (VT) circuits is limited by insufficient spa

258 Inducibility of ventricular tachycardia (VT) has limited ability to predict recurren

259 Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic right ventricular car

260 blation of sustained monomorphic ventricular tachycardia (VT) in LMNA cardiomyopathy.

261 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with cardiac sarcoidosis ca

262 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with nonischemic dilated ca

263 comes after catheter ablation of ventricular tachycardia (VT) in patients with nonischemic dilated ca

264 Ventricular tachycardia (VT) is a major cause of sudden cardiac deat

265 Catheter ablation of ventricular tachycardia (VT) is being increasingly performed; yet, t

266 entricular activities (LAVA) and ventricular tachycardia (VT) noninducibility.

267 end point was the first event of ventricular tachycardia (VT) or fibrillation (VF).

268 Ventricular tachycardia (VT) radiofrequency ablation has been associ

269 ort with multiple side branches, ventricular tachycardia (VT) supporting channels have very slow impu

270 In contrast to ventricular tachycardia (VT) that occurs in the setting of a structu

271 (2) quantify their risk of death/ventricular tachycardia (VT), and (3) identify imaging-based covaria

272 ation is used to treat recurrent ventricular tachycardia (VT).

273 CACNA1C gene are associated with ventricular tachycardia (VT).

274 h for simulating infarct-related ventricular tachycardia (VT).

275 ular pathological remodeling and ventricular tachycardia (VT).

276 : 63 (group 1) having documented ventricular tachycardia (VT)/ventricular fibrillation (VF) and Bruga

277 out NSVT experienced ICD-treated ventricular tachycardia (VT)/ventricular fibrillation (VF).

278 CDs, history of >/=1 ICD-treated ventricular tachycardias (VT)/ventricular fibrillation episode, or a

279 dence of sudden cardiac death or ventricular tachycardia was 41% at 1 year and 55% at 5 years.

280 procedures, freedom from recurrent AF/atrial tachycardia was achieved in 87%.

281 Tachycardia was also higher in patients given placebo (4

282 The diastolic isthmus in ventricular tachycardia was mapped in 3 patients and colocated withi

283 Recurrence of tachycardia was more likely in patients with complex sur

284 Ventricular tachycardia was noninducible in 85% of patients post abl

285 Tachycardia was observed briefly, but only after the cor

286 icular fibrillation or pulseless ventricular tachycardia was refractory to shock.

287 the rate of recurrent arrhythmia (AF/atrial tachycardia) was 21% at 1 year, 11% between 1 and 3 year

288 Oxygen saturation of </=90%, tachypnea, and tachycardia were each associated with an increased odds

289 nd catecholaminergic polymorphic ventricular tachycardia were the most common diagnoses.

290 Right posteroseptal AP tachycardias were distinctly characterized by atrial res

291 Twenty-three left-sided atrial tachycardias were mapped in 15 patients (age: 64+/-11 ye

292 eural effusions and another with ventricular tachycardia, were not successfully gated.

293 rial fibrillation, atrial flutter, or atrial tachycardia while not receiving antiarrhythmic medicatio

294 frequently misdiagnosed as supraventricular tachycardia with aberrant right bundle branch block (RBB

295 f right ventricular scar-related ventricular tachycardia with computed tomographic image integration,

296 ome characterized by polymorphic ventricular tachycardia with physical or emotional stress, for which

297 llation and those with sustained ventricular tachycardia with syncope or systolic heart failure as a

298 e or more documented episodes of ventricular tachycardia within 24 hours (ventricular tachycardia sto

299 ered at heart rates >/= 170 bpm (ventricular tachycardia zone) and at rates >/= 200 bpm (ventricular

300 ct therapy to regular rhythms in ventricular tachycardia zones.